The abstract is read at the publisher; the summary is JClub's.
FUS-enhanced BBB opening in a 9-compartment CNS PBPK model shows that timing and BBB transport kinetics jointly govern CNS pharmacokinetics, with maximal tumor penetration when dosing overlaps opening.
- Why it matters: Clinical translation of focused ultrasound BBB opening for brain cancer therapy is limited by insufficient quantitative understanding of how drugs distribute in the CNS after FUS.
- What they did: The authors extended a validated 9-compartment CNS PBPK framework to include FUS-defined BBB opening onset, duration, and magnitude across tumor compartments T1–T3, simulating trastuzumab, T-DM1, T-DXd, and temozolomide.
- The result: Simulations predict that concurrent BBB opening and drug dosing maximizes tumor penetration for all four agents; T-DM1 and T-DXd are most likely to gain intracranial efficacy, whereas trastuzumab is not, and temozolomide benefit may depend on favorable tumor biology.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.